Halozyme Therapeutics, Inc. - Understand $halo stock

$HALO Market Cap: $6.185 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$947.4M

TTM

Gross Margin

82.16%

TTM

Net Earnings

$392.5M

TTM

Current Assets

$1.127B

Q3 2024

Current Liabilities

$108.8M

Q3 2024

Current Ratio

1035.68%

Q3 2024

Total Assets

$2.118B

Q3 2024

Total Liabilities

$1.665B

Q3 2024

Book Value

$452.7M

Q3 2024

Cash

$154.3M

Q3 2024

P/E

15.76

Nov 29, 2024 EST

Free Cash Flow

$392.7M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	$829.3M	$660.1M	$443.3M	$267.6M	$196.0M	$151.9M	$316.6M	$146.7M	$135.1M	$75.33M	$54.80M	$42.33M	$56.09M	$13.62M	$13.70M	$8.800M	$3.800M	$1.000M	$100.0K	$0.00	$0.00	$0.00
YoY Change	25.62%	48.91%	65.67%	36.53%	29.06%	-52.04%	115.84%	8.61%	79.28%	37.47%	29.47%	-24.54%	311.67%	-0.55%	55.68%	131.58%	280.0%	900.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	$829.3M	$660.1M	$443.3M	$267.6M	$196.0M	$151.9M	$316.6M	$146.7M	$135.1M	$75.33M	$54.80M	$42.33M	$56.09M	$13.62M	$13.70M	$8.800M	$3.800M	$1.000M	$100.0K	$0.00	$0.00	$0.00
Cost Of Revenue	$192.4M	$139.3M	$81.41M	$43.37M	$45.55M	$10.14M	$31.15M	$33.21M	$29.25M	$22.73M	$6.246M	$1.094M	$257.8K	$985.3K	$300.0K	$300.0K	$200.0K	$400.0K	$100.0K	$0.00
Gross Profit	$636.9M	$520.8M	$361.9M	$224.2M	$150.4M	$141.7M	$285.5M	$113.5M	$105.8M	$52.60M	$48.55M	$41.23M	$55.83M	$12.64M	$13.40M	$8.400M	$3.600M	$500.0K	$100.0K	$0.00
Gross Profit Margin	76.8%	78.9%	81.64%	83.79%	76.76%	93.33%	90.16%	77.36%	78.35%	69.83%	88.6%	97.42%	99.54%	92.77%	97.81%	95.45%	94.74%	50.0%	100.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Selling, General & Admin	$149.2M	$143.5M	$50.32M	$45.74M	$77.25M	$60.80M	$53.82M	$45.85M	$40.03M	$35.94M	$32.35M	$24.81M	$18.10M	$15.12M	$15.20M	$14.60M	$11.20M	$6.900M	$3.400M	$2.600M	$600.0K	$400.0K
YoY Change	3.94%	185.21%	10.03%	-40.8%	27.05%	12.98%	17.37%	14.55%	11.37%	11.11%	30.37%	37.05%	19.71%	-0.51%	4.11%	30.36%	62.32%	102.94%	30.77%	333.33%	50.0%
% of Gross Profit	23.42%	27.56%	13.91%	20.4%	51.35%	42.9%	18.85%	40.4%	37.83%	68.33%	66.62%	60.18%	32.43%	119.65%	113.43%	173.81%	311.11%	1380.0%	3400.0%
Research & Development	$76.36M	$66.61M	$35.67M	$34.24M	$140.8M	$150.3M	$150.6M	$150.8M	$93.24M	$79.70M	$96.64M	$70.04M	$57.56M	$51.77M	$56.60M	$44.20M	$20.60M	$9.200M	$10.20M	$6.500M	$1.100M	$800.0K
YoY Change	14.65%	86.72%	4.19%	-75.69%	-6.29%	-0.26%	-0.13%	61.79%	16.99%	-17.53%	37.97%	21.68%	11.18%	-8.53%	28.05%	114.56%	123.91%	-9.8%	56.92%	490.91%	37.5%
% of Gross Profit	11.99%	12.79%	9.86%	15.27%	93.59%	106.02%	52.77%	132.92%	88.11%	151.51%	199.04%	169.88%	103.11%	409.64%	422.39%	526.19%	572.22%	1840.0%	10200.0%
Depreciation & Amortization	$11.10M	$6.500M	$3.000M	$3.300M	$4.100M	$2.400M	$2.200M	$2.400M	$1.677M	$1.762M	$1.227M	$1.079M	$1.096M	$1.508M	$1.400M	$1.000M	$600.0K	$200.0K	$200.0K	$100.0K	$100.0K	$100.0K
YoY Change	70.77%	116.67%	-9.09%	-19.51%	70.83%	9.09%	-8.33%	43.11%	-4.82%	43.6%	13.72%	-1.54%	-27.33%	7.71%	40.0%	66.67%	200.0%	0.0%	100.0%	0.0%	0.0%
% of Gross Profit	1.74%	1.25%	0.83%	1.47%	2.73%	1.69%	0.77%	2.11%	1.58%	3.35%	2.53%	2.62%	1.96%	11.93%	10.45%	11.9%	16.67%	40.0%	200.0%
Operating Expenses	$225.5M	$210.1M	$86.00M	$79.97M	$218.1M	$211.1M	$204.5M	$196.7M	$133.3M	$115.6M	$129.0M	$94.86M	$75.67M	$66.90M	$71.80M	$58.90M	$31.70M	$16.20M	$13.60M	$9.100M	$1.700M	$1.200M
YoY Change	7.33%	144.35%	7.53%	-63.33%	3.32%	3.23%	3.95%	47.6%	15.24%	-10.35%	35.98%	25.36%	13.11%	-6.83%	21.9%	85.8%	95.68%	19.12%	49.45%	435.29%	41.67%
Operating Profit	$337.6M	$267.5M	$275.9M	$144.3M	-$67.61M	-$69.33M	$81.00M	-$83.21M	-$27.45M	-$63.04M	-$80.43M	-$53.63M	-$19.84M	-$54.26M	-$58.40M	-$50.50M	-$28.10M	-$15.70M	-$13.50M	-$9.100M
YoY Change	26.18%	-3.03%	91.26%	-313.36%	-2.48%	-185.59%	-197.35%	203.11%	-56.45%	-21.63%	49.99%	170.3%	-63.44%	-7.09%	15.64%	79.72%	78.98%	16.3%	48.35%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Interest Expense	$18.76M	$16.95M	$7.526M	$20.38M	$11.63M	$18.04M	$21.98M	$19.98M	$5.201M	$5.581M	$3.274M	$0.00	$0.00	$0.00	$100.0K	$1.700M	$4.300M	$800.0K	$300.0K		-$400.0K	$0.00
YoY Change	10.71%	125.18%	-63.07%	75.26%	-35.55%	-17.94%	10.05%	284.1%	-6.81%	70.46%				-100.0%	-94.12%	-60.47%	437.5%	166.67%
% of Operating Profit	5.56%	6.33%	2.73%	14.13%			27.14%
Other Income/Expense, Net	$16.32M	$1.046M	$1.102M	$5.425M	$6.986M	$7.578M	$2.592M	$1.326M	$422.0K			$73.44K	$69.09K	$1.016M	$0.00	$0.00				$0.00	$0.00	$0.00
YoY Change	1459.94%	-5.08%	-79.69%	-22.34%	-7.81%	192.36%	95.48%	214.22%				6.3%	-93.2%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Pretax Income	$348.3M	$248.9M	$248.5M	$129.3M	-$72.25M	-$79.79M	$61.61M	-$101.9M	-$32.23M	-$68.38M	-$83.50M	-$53.60M	-$19.80M	-$53.20M	-$58.40M	-$48.70M	-$23.90M	-$14.80M	-$13.30M	-$9.100M	-$2.100M	-$1.100M
YoY Change	39.94%	0.16%	92.2%	-278.96%	-9.45%	-229.51%	-160.48%	216.03%	-52.86%	-18.11%	55.78%	170.71%	-62.78%	-8.9%	19.92%	103.77%	61.49%	11.28%	46.15%	333.33%	90.91%
Income Tax	$66.74M	$46.79M	-$154.2M	$217.0K	-$11.00K	$537.0K	-$1.361M	$1.162M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	-$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income	19.16%	18.8%	-62.04%	0.17%			-2.21%
Net Earnings	$281.6M	$202.1M	$402.7M	$129.1M	-$72.24M	-$80.33M	$62.97M	-$103.0M	-$32.23M	-$68.38M	-$83.48M	-$53.55M	-$19.77M	-$53.24M	-$58.40M	-$48.70M	-$23.90M	-$14.80M	-$13.30M	-$9.100M	-$2.100M	-$1.100M
YoY Change	39.31%	-49.81%	211.97%	-278.69%	-10.07%	-227.57%	-161.12%	219.64%	-52.86%	-18.09%	55.88%	170.88%	-62.87%	-8.83%	19.92%	103.77%	61.49%	11.28%	46.15%	333.33%	90.91%
Net Earnings / Revenue	33.96%	30.62%	90.84%	48.24%	-36.86%	-52.9%	19.89%	-70.23%	-23.86%	-90.76%	-152.34%	-126.53%	-35.25%	-390.79%	-426.28%	-553.41%	-628.95%	-1480.0%	-13300.0%
Basic Earnings Per Share	$2.13	$1.48	$2.86	$0.95	-$0.50	-$0.56	$0.46	-$0.81	-$0.25
Diluted Earnings Per Share	$2.10	$1.44	$2.74	$0.91	-$0.50	-$0.56	$0.45	-$0.81	-$0.25	-$557.5K	-$740.2K	-$482.4K	-$193.0K	-$563.6K	-$673.6K	-$610.3K	-$321.7K	-$236.4K	-$264.4K	-$257.1K	-$308.8K	-$239.1K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Cash & Short-Term Investments	$336.0M	$362.8M	$740.9M	$368.0M	$421.3M	$354.5M	$469.2M	$205.0M	$108.3M	$135.6M	$71.50M	$99.50M	$52.80M	$83.30M	$67.50M	$63.70M	$97.70M	$44.20M	$19.10M	$16.00M	$500.0K	$100.0K
YoY Change	-7.39%	-51.03%	101.34%	-12.65%	18.84%	-24.45%	128.88%	89.29%	-20.13%	89.65%	-28.14%	88.45%	-36.61%	23.41%	5.97%	-34.8%	121.04%	131.41%	19.38%	3100.0%	400.0%
Cash & Equivalents	$118.4M	$234.2M	$118.7M	$147.7M	$120.2M	$57.90M	$168.7M	$66.80M	$43.30M	$61.40M	$27.40M	$99.50M	$52.80M	$83.30M	$67.50M	$63.70M	$97.70M	$44.20M	$19.10M	$16.00M	$500.0K	$100.0K
Short-Term Investments	$217.6M	$128.6M	$622.2M	$220.3M	$301.1M	$296.6M	$300.5M	$138.2M	$65.00M	$74.20M	$44.10M	$0.00
Other Short-Term Assets	$48.61M	$45.02M	$40.48M	$28.30M	$33.40M	$20.70M	$13.90M	$21.20M	$21.50M	$10.10M	$8.400M	$12.80M	$8.300M	$3.700M	$1.600M	$2.600M	$2.000M	$600.0K	$300.0K	$100.0K
YoY Change	7.97%	11.22%	43.05%	-15.27%	61.35%	48.92%	-34.43%	-1.4%	112.87%	20.24%	-34.38%	54.22%	124.32%	131.25%	-38.46%	30.0%	233.33%	100.0%	200.0%
Inventory	$127.6M	$100.1M	$53.91M	$60.70M	$29.40M	$22.60M	$5.100M	$14.60M	$9.500M	$6.400M	$6.200M	$2.700M	$600.0K	$200.0K	$1.200M	$400.0K	$700.0K	$400.0K	$300.0K	$100.0K
Prepaid Expenses
Receivables	$234.2M	$231.1M	$90.98M	$97.70M	$59.40M	$30.00M	$22.10M	$15.70M	$32.40M	$9.100M	$9.100M	$15.70M	$2.300M	$2.300M	$4.200M	$7.300M	$800.0K	$400.0K	$400.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$746.4M	$739.0M	$926.3M	$554.8M	$543.4M	$427.8M	$510.4M	$256.5M	$171.8M	$161.3M	$95.20M	$130.6M	$64.00M	$89.50M	$74.40M	$74.00M	$101.2M	$45.60M	$20.10M	$16.10M	$500.0K	$100.0K
YoY Change	1.0%	-20.22%	66.96%	2.1%	27.02%	-16.18%	98.99%	49.3%	6.51%	69.43%	-27.11%	104.06%	-28.49%	20.3%	0.54%	-26.88%	121.93%	126.87%	24.84%	3120.0%	400.0%
Property, Plant & Equipment	$74.94M	$75.57M	$8.794M	$10.60M	$10.90M	$7.500M	$3.500M	$4.300M	$3.900M	$3.000M	$3.400M	$3.700M	$1.800M	$1.800M	$2.700M	$2.600M	$2.300M	$500.0K	$400.0K	$200.0K	$100.0K	$100.0K
YoY Change	-0.83%	759.34%	-17.04%	-2.75%	45.33%	114.29%	-18.6%	10.26%	30.0%	-11.76%	-8.11%	105.56%	0.0%	-33.33%	3.85%	13.04%	360.0%	25.0%	100.0%	100.0%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$22.20M	$71.23M	$169.3M	$14.60M	$11.60M	$4.900M	$6.100M	$700.0K	$6.100M	$1.700M	$3.200M	$400.0K							$0.00	$0.00	$0.00	$0.00
YoY Change	-68.83%	-57.94%	1059.92%	25.86%	136.73%	-19.67%	771.43%	-88.52%	258.82%	-46.88%	700.0%
Total Long-Term Assets	$986.8M	$1.102B	$178.1M	$25.10M	$22.50M	$12.40M	$9.500M	$5.000M	$10.00M	$4.700M	$6.600M	$4.100M	$1.800M	$1.800M	$2.700M	$2.600M	$2.300M	$500.0K	$400.0K	$300.0K	$100.0K	$100.0K
YoY Change	-10.49%	518.89%	609.73%	11.56%	81.45%	30.53%	90.0%	-50.0%	112.77%	-28.79%	60.98%	127.78%	0.0%	-33.33%	3.85%	13.04%	360.0%	25.0%	33.33%	200.0%	0.0%
Total Assets	$1.733B	$1.842B	$1.104B	$579.9M	$565.9M	$440.2M	$519.9M	$261.5M	$181.8M	$166.0M	$101.8M	$134.7M	$65.80M	$91.30M	$77.10M	$76.60M	$103.5M	$46.10M	$20.50M	$16.40M	$600.0K	$200.0K
YoY Change
Accounts Payable	$11.82M	$17.69M	$1.541M	$1.900M	$6.400M	$4.100M	$7.900M	$3.600M	$4.500M	$3.000M	$3.100M	$2.300M	$7.600M	$3.800M	$2.800M	$6.700M	$3.100M	$2.000M	$1.400M	$1.500M	$200.0K	$100.0K
YoY Change	-33.22%	1048.15%	-18.89%	-70.31%	56.1%	-48.1%	119.44%	-20.0%	50.0%	-3.23%	34.78%	-69.74%	100.0%	35.71%	-58.21%	116.13%	55.0%	42.86%	-6.67%	650.0%	100.0%
Accrued Expenses	$99.72M	$96.52M	$24.44M	$20.50M	$55.60M	$49.50M	$39.60M	$28.80M	$26.80M	$14.00M	$14.40M	$7.800M	$5.600M	$8.600M	$6.100M	$4.000M	$2.500M	$1.000M	$700.0K	$100.0K	$100.0K	$100.0K
YoY Change	3.31%	294.89%	19.22%	-63.13%	12.32%	25.0%	37.5%	7.46%	91.43%	-2.78%	84.62%	39.29%	-34.88%	40.98%	52.5%	60.0%	150.0%	42.86%	600.0%	0.0%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$400.0K
YoY Change																					-100.0%
Long-Term Debt Due	$0.00	$13.33M	$89.42M	$397.2M	$19.50M	$91.50M	$77.20M	$17.40M	$21.90M		$0.00	$0.00
YoY Change	-100.0%	-85.09%	-77.49%	1936.92%	-78.69%	18.52%	343.68%	-20.55%
Total Short-Term Liabilities	$112.5M	$130.8M	$117.1M	$421.4M	$85.60M	$149.4M	$131.3M	$54.60M	$62.50M	$24.30M	$24.90M	$18.90M	$17.30M	$15.30M	$14.40M	$14.20M	$8.900M	$4.300M	$2.300M	$1.600M	$300.0K	$600.0K
YoY Change	-13.99%	11.65%	-72.2%	392.29%	-42.7%	13.79%	140.48%	-12.64%	157.2%	-2.41%	31.75%	9.25%	13.07%	6.25%	1.41%	59.55%	106.98%	86.96%	43.75%	433.33%	-50.0%
Long-Term Debt	$1.499B	$1.493B	$787.3M	$0.00	$383.0M	$34.90M	$125.1M	$199.2M	$28.00M	$49.90M	$49.80M	$31.10M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	0.43%	89.62%		-100.0%	997.42%	-72.1%	-37.2%	611.43%	-43.89%	0.2%	60.13%
Other Long-Term Liabilities	$37.72M	$48.16M	$3.074M	$7.500M	$5.400M	$7.100M	$55.10M	$40.20M	$48.40M	$50.40M	$47.10M	$35.80M	$37.60M	$55.70M	$55.80M	$47.00M	$36.80M	$18.80M	$0.00
YoY Change	-21.67%	1466.62%	-59.01%	38.89%	-23.94%	-87.11%	37.06%	-16.94%	-3.97%	7.01%	31.56%	-4.79%	-32.5%	-0.18%	18.72%	27.72%	95.74%
Total Long-Term Liabilities	$1.537B	$1.541B	$790.3M	$7.500M	$388.4M	$42.00M	$180.2M	$239.4M	$76.40M	$100.3M	$96.90M	$66.90M	$37.60M	$55.70M	$55.80M	$47.00M	$36.80M	$18.80M	$0.00	$0.00	$0.00	$0.00
YoY Change	-0.26%	94.97%	10437.72%	-98.07%	824.76%	-76.69%	-24.73%	213.35%	-23.83%	3.51%	44.84%	77.93%	-32.5%	-0.18%	18.72%	27.72%	95.74%
Total Liabilities	$1.649B	$1.672B	$907.5M	$428.9M	$474.1M	$191.4M	$311.6M	$294.0M	$138.8M	$124.6M	$121.8M	$85.90M	$54.90M	$71.00M	$70.20M	$61.20M	$45.70M	$23.00M	$2.300M	$1.600M	$300.0K	$600.0K
YoY Change	-1.33%	84.22%	111.58%	-9.53%	147.7%	-38.58%	5.99%	111.82%	11.4%	2.3%	41.79%	56.47%	-22.68%	1.14%	14.71%	33.92%	98.7%	900.0%	43.75%	433.33%	-50.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015
Basic Shares Outstanding	131.9M shares	136.8M shares	140.6M shares	136.2M shares	144.3M shares	143.6M shares	136.4M shares	128.0M shares	126.7M shares
Diluted Shares Outstanding	134.2M shares	140.6M shares	146.8M shares	141.5M shares	144.3M shares	143.6M shares	139.1M shares	128.0M shares	126.7M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $6.1845 Billion

About HALOZYME THERAPEUTICS, INC.

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 373 full-time employees. The company went IPO on 2003-01-30. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. The company also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. The company markets and sells Hylenex recombinant, which is a formulation of rHuPH20. The company markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Industry: Biological Products, (No Diagnostic Substances) Peers: Cerevel Therapeutics Holdings, Inc. CYTOKINETICS INC EXACT SCIENCES CORP EXELIXIS, INC. Global Blood Therapeutics, Inc. IONIS PHARMACEUTICALS INC Legend Biotech Corp